Clinical Trial Search

Primary: Change in Esthetic Properties: Number of Teeth, Rated 1 (Most Desirable Outcome) to 5 (Least Desirable Outcome), in Each Esthetic Category — 25; 25; 2; 2 Teeth

Primary: Subjective Perception of Mouth Dryness — 6.92; 6.46; 4.21; 3.46 units on a scale — p=.45

Primary: Plaque Index — 0.55; 0.41; 0.48 Proportion of sites with plaque deposits — p=0.939

Primary: Response Rate — 0; 0; 26; 11 Participants

Primary: Bacterial Count of Streptococus Mutans — 2.00; 2.04; 1.12; 1.05 CFU/ml log10

Primary: Event Free Survival — 3.48; 4.96 months

Primary: Progression-free Survival (PFS) — 4.83; 7.23 months

Primary: Progression-free Survival (PFS) — 7.2; 13.0 months

Primary: Progression Free Survival — 6.2; 7.5 months

Primary: Overall Survival (OS) — 46.3; 58.1; 52.9 months — p=0.4051

Primary: Number of Participants With Changes in Putative Tumor Initiating Cell Populations as Defined by Cell Surface CD44 and Intracellular Phospho-ERK1/2 Staining After…

Primary: Event-free Survival (EFS)- Number of Participants With an Event — 31; 15 Participants

Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants

Primary: 6 Month Progression Free Survival (PFS) — 2.8; NA Months

Primary: Net Change Relative to Baseline in Tumor Blood Flow — -0.44; -0.12; -0.60; -0.40 ml/min/100gm